Opiate receptor binding: effects of enzymatic treatments

G. W. Pasternak, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

A variety of enzymatic treatments were examined with regard to their effect on stereospecific [3H]naloxone binding to rat brain homogenates. Opiate receptor binding is sensitive to very low concentrations of trypsin (EC 3.4.4.4) and chymotrypsin (EC 3.4.4.5). Trypsin appears to decrease the number of opiate receptor binding sites, while chymotrypsin primarily lowers their affinity for opiates. Receptor binding is drastically reduced by very low concentrations of phospholipase A (EC 3.1.1.4), is decreased by higher concentrations of phospholipase C (EC 3.1.4.3), and appears relatively insensitive to phospholipase D (EC 3.1.4.4) and neuraminidase (EC 3.2.1.18). Small amounts of RNase (EC 2.7.7.16) and DNase (EC 3.1.4.5) are without effect. Trypsin and chymotrypsin decrease receptor binding in a biphasic fashion, suggesting the presence of more than one population of sites sensitive to proteolysis. By contrast, the phospholipases degrade binding in a monophasic fashion. Thus the opiate receptor appears to be a membrane bound complex whose stereospecific binding is dependent upon the integrity of both proteins and phospholipids.

Original languageEnglish (US)
Pages (from-to)183-193
Number of pages11
JournalMolecular Pharmacology
Volume10
Issue number2
StatePublished - 1974

Fingerprint

Opioid Receptors
Chymotrypsin
Trypsin
Opiate Alkaloids
Phospholipase D
Deoxyribonucleases
Phospholipases
Phospholipases A
Neuraminidase
Type C Phospholipases
Vulnerable Populations
Ribonucleases
Naloxone
Proteolysis
Phospholipids
Therapeutics
Binding Sites
Membranes
Brain
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Opiate receptor binding : effects of enzymatic treatments. / Pasternak, G. W.; Snyder, Solomon H.

In: Molecular Pharmacology, Vol. 10, No. 2, 1974, p. 183-193.

Research output: Contribution to journalArticle

@article{c372345f789543928a56ba634fafb7ec,
title = "Opiate receptor binding: effects of enzymatic treatments",
abstract = "A variety of enzymatic treatments were examined with regard to their effect on stereospecific [3H]naloxone binding to rat brain homogenates. Opiate receptor binding is sensitive to very low concentrations of trypsin (EC 3.4.4.4) and chymotrypsin (EC 3.4.4.5). Trypsin appears to decrease the number of opiate receptor binding sites, while chymotrypsin primarily lowers their affinity for opiates. Receptor binding is drastically reduced by very low concentrations of phospholipase A (EC 3.1.1.4), is decreased by higher concentrations of phospholipase C (EC 3.1.4.3), and appears relatively insensitive to phospholipase D (EC 3.1.4.4) and neuraminidase (EC 3.2.1.18). Small amounts of RNase (EC 2.7.7.16) and DNase (EC 3.1.4.5) are without effect. Trypsin and chymotrypsin decrease receptor binding in a biphasic fashion, suggesting the presence of more than one population of sites sensitive to proteolysis. By contrast, the phospholipases degrade binding in a monophasic fashion. Thus the opiate receptor appears to be a membrane bound complex whose stereospecific binding is dependent upon the integrity of both proteins and phospholipids.",
author = "Pasternak, {G. W.} and Snyder, {Solomon H}",
year = "1974",
language = "English (US)",
volume = "10",
pages = "183--193",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Opiate receptor binding

T2 - effects of enzymatic treatments

AU - Pasternak, G. W.

AU - Snyder, Solomon H

PY - 1974

Y1 - 1974

N2 - A variety of enzymatic treatments were examined with regard to their effect on stereospecific [3H]naloxone binding to rat brain homogenates. Opiate receptor binding is sensitive to very low concentrations of trypsin (EC 3.4.4.4) and chymotrypsin (EC 3.4.4.5). Trypsin appears to decrease the number of opiate receptor binding sites, while chymotrypsin primarily lowers their affinity for opiates. Receptor binding is drastically reduced by very low concentrations of phospholipase A (EC 3.1.1.4), is decreased by higher concentrations of phospholipase C (EC 3.1.4.3), and appears relatively insensitive to phospholipase D (EC 3.1.4.4) and neuraminidase (EC 3.2.1.18). Small amounts of RNase (EC 2.7.7.16) and DNase (EC 3.1.4.5) are without effect. Trypsin and chymotrypsin decrease receptor binding in a biphasic fashion, suggesting the presence of more than one population of sites sensitive to proteolysis. By contrast, the phospholipases degrade binding in a monophasic fashion. Thus the opiate receptor appears to be a membrane bound complex whose stereospecific binding is dependent upon the integrity of both proteins and phospholipids.

AB - A variety of enzymatic treatments were examined with regard to their effect on stereospecific [3H]naloxone binding to rat brain homogenates. Opiate receptor binding is sensitive to very low concentrations of trypsin (EC 3.4.4.4) and chymotrypsin (EC 3.4.4.5). Trypsin appears to decrease the number of opiate receptor binding sites, while chymotrypsin primarily lowers their affinity for opiates. Receptor binding is drastically reduced by very low concentrations of phospholipase A (EC 3.1.1.4), is decreased by higher concentrations of phospholipase C (EC 3.1.4.3), and appears relatively insensitive to phospholipase D (EC 3.1.4.4) and neuraminidase (EC 3.2.1.18). Small amounts of RNase (EC 2.7.7.16) and DNase (EC 3.1.4.5) are without effect. Trypsin and chymotrypsin decrease receptor binding in a biphasic fashion, suggesting the presence of more than one population of sites sensitive to proteolysis. By contrast, the phospholipases degrade binding in a monophasic fashion. Thus the opiate receptor appears to be a membrane bound complex whose stereospecific binding is dependent upon the integrity of both proteins and phospholipids.

UR - http://www.scopus.com/inward/record.url?scp=0015987492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015987492&partnerID=8YFLogxK

M3 - Article

C2 - 4212212

AN - SCOPUS:0015987492

VL - 10

SP - 183

EP - 193

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -